Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Drug Profile

Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine
  • Class Antihyperglycaemics; Cardiovascular therapies; Glucosides; Heart failure therapies; Obesity therapies; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Heart failure; Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 07 Sep 2018 The European Commission approves the label update to include data on reduction in risk for major cardiovascular events in patients with Type 2 diabetes mellitus
  • 02 Aug 2018 The Committee for Medicinal Products for Human Use recommends update in label to include data on reduction in risk for major cardiovascular events in patients with Type 2 diabetes mellitus in European Union
  • 24 Jul 2018 Kyoto Prefectural University of Medicine completes a clinical trial for Type-2 diabetes mellitus in Japan, before July 2018 (UMIN000023044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top